唾液microRNA特征诊断子宫内膜异位症:Endotest®的成本效果评价
本研究基于文献数据构建决策树模型,在法国慢性盆腔痛女性中比较四种诊断策略的成本与准确率。以Endotest®定价750欧元时,策略I被其他策略支配;策略IV、III、II分别在支付意愿阈值低于473欧元、473至4670欧元、高于4670欧元时更优。
要点
- Endotest®定价750欧元时,策略I、II、III、IV每正确诊断一例的成本分别为1542、990、919、1000欧元。
- 策略I被所有其他策略支配;策略IV、III、II分别在支付意愿阈值低于473欧元、473至4670欧元、高于4670欧元时更优。
- Endotest®定价500欧元时策略I被所有其他策略支配;定价1000欧元时策略II和III相比策略I的ICER分别为724和387欧元。
核心结论
- 本研究从经济学角度证明了Endotest®的价值。
研究设计与样本
- 基于文献数据的决策树模型成本效果分析,地点为法国,目标人群为慢性盆腔痛女性。
- 策略I为法国常规路径(对照),策略II为所有患者行Endotest®,策略III为超声未检出子宫内膜瘤者行Endotest®,策略IV为超声未检出子宫内膜瘤者行盆腔MRI后MRI阴性者行Endotest®。
- 分别按Endotest®定价500、750、1000欧元进行三种分析,并行蒙特卡洛模拟的概率敏感性分析。
主要发现
- Endotest®定价750欧元时,策略I、II、III、IV每正确诊断一例的成本分别为1542、990、919、1000欧元。
- 策略I被所有其他策略支配;策略IV、III、II分别在支付意愿阈值低于473欧元、473至4670欧元、高于4670欧元时更优。
- Endotest®定价500欧元时,策略I被所有其他策略支配。
- Endotest®定价1000欧元时,策略II和III相比策略I的ICER分别为每正确诊断一例724和387欧元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate a saliva diagnostic test (Endotest®) for endometriosis compared with the conventional algorithm. DESIGN: A cost-effectiveness analysis with a decision-tree model based on literature data. SETTING: France. POPULATION: Women with chronic pelvic pain. METHODS: Strategy I is the French algorithm, representing the comparator. For strategy II, all patients have an Endotest®. For strategy III, patients undergo ultrasonography to detect endometrioma and patients with no endometrioma detected have an Endotest®. For strategy IV, patients with no endometrioma detected on ultrasonography undergo pelvic magnetic resonance imaging (MRI) to detect endometrioma and/or deep endometriosis. An Endotest® is then performed for patients with a negative result on MRI. MAIN OUTCOMES MEASURES: Costs and accuracy rates and incremental cost-effectiveness ratios (ICERs). Three analyses were performed with an Endotest® priced at €500, €750, and €1000. Probabilistic sensitivity analysis was conducted with Monte Carlo simulations. RESULTS: With an Endotest® priced at €750, the cost per correctly diagnosed case was €1542, €990, €919 and €1000, respectively, for strategies I, II, III and IV. Strategy I was dominated by all other strategies. Strategies IV, III and II were, respectively, preferred for a willingness-to-pay threshold below €473, between €473 and €4670, and beyond €4670 per correctly diagnosed case. At a price of €500 per Endotest®, strategy I was dominated by all other strategies. At €1000, the ICERs of strategies II and III were €724 and €387 per correctly diagnosed case, respectively, compared with strategy I. CONCLUSION: The present study demonstrates the value of the Endotest® from an economic perspective.
引用
- Ferrier C, Bendifallah S, Suisse S, et al. Saliva microRNA signature to diagnose endometriosis: A cost-effectiveness evaluation of the Endotest®. BJOG. 2022. PMID: 36424910. doi:10.1111/1471-0528.17348
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。